Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with 177Lu and Conjugated to Peptides

Author(s): Guillermina Ferro-Flores, Blanca E. Ocampo-García, Clara L. Santos-Cuevas, Flor de María Ramírez, Erika P. Azorín-Vega, Laura Meléndez-Alafort.

Journal Name: Current Radiopharmaceuticals

Volume 8 , Issue 2 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Gold nanoparticles (AuNPs) have been proposed for a variety of medical applications such as localized heat sources for cancer treatment and drug delivery systems. The conjugation of peptides to AuNPs produces stable multimeric systems with target-specific molecular recognition. Lutetium- 177 (177Lu) has been successfully used in peptide radionuclide therapy. Recently, 177Lu-AuNPs conjugated to different peptides have been proposed as a new class of theranostic radiopharmaceuticals. These radioconjugates may function simultaneously as molecular imaging agents, radiotherapy systems and thermal-ablation systems. This article covers advancements in the design, synthesis, physicochemical characterization, molecular recognition assessment and preclinical therapeutic efficacy of gold nanoparticles radiolabeled with 177Lu and conjugated to RGD (-Arg-Gly-Asp-), Lys3-Bombesin and Tat(49-57) peptides.

Keywords: Bombesin, cancer thermotherapy, gold nanoparticles, gold nanoparticles-peptides, lutetium-177, RGD, targeted radiotherapy, Tat-peptides.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 2
Year: 2015
Page: [150 - 159]
Pages: 10
DOI: 10.2174/1874471008666150313115423
Price: $58

Article Metrics

PDF: 27
HTML: 1